Hi, Amy.
They say it can be useful for pseudomona too, although so far it has only being evaluated for mrsa, so I hope it will be able to help you too <img src="i/expressions/face-icon-small-smile.gif" border="0"> (And my boyfriend one day when he´d get it). It seems to be a very broad spectrum antibiotic so hopefully it will help a lot of people. We´ll see...
BTW I agree with you
1: Clin Microbiol Infect. 2007 Jun;13(6):560-78. Epub 2007 Jan 31. Links
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F.
Unité de Pharmacologie cellulaire and moléculaire, Université catholique de Louvain, Bruxelles, Belgium.
Pseudomonas aeruginosa is a major cause of nosocomial infections. This organism shows a remarkable capacity to resist antibiotics, either intrinsically (because of constitutive expression of beta-lactamases and efflux pumps, combined with low permeability of the outer-membrane) or following acquisition of resistance genes (e.g., genes for beta-lactamases, or enzymes inactivating aminoglycosides or modifying their target), over-expression of efflux pumps, decreased expression of porins, or mutations in quinolone targets. Worryingly, these mechanisms are often present simultaneously, thereby conferring multiresistant phenotypes. Susceptibility testing is therefore crucial in clinical practice. Empirical treatment usually involves combination therapy, selected on the basis of known local epidemiology (usually a beta-lactam plus an aminoglycoside or a fluoroquinolone). However, therapy should be simplified as soon as possible, based on susceptibility data and the patient's clinical evolution. Alternative drugs (e.g., colistin) have proven useful against multiresistant strains, but innovative therapeutic options for the future remain scarce, while attempts to develop vaccines have been unsuccessful to date. <span class="FTHighlightFont"><span class="FTHighlightFont">Among broad-spectrum antibiotics in development, ceftobiprole</span ft>, sitafloxacin and doripenem show interesting in-vitro activity, although the first two molecules have been evaluated in clinics only against Gram-positive organisms.</span ft> Doripenem has received a fast track designation from the US Food and Drug Administration for the treatment of nosocomial pneumonia. Pump inhibitors are undergoing phase I trials in cystic fibrosis patients. Therefore, selecting appropriate antibiotics and optimising their use on the basis of pharmacodynamic concepts currently remains the best way of coping with pseudomonal infections.
PMID: 17266725 [PubMed - indexed for MEDLINE]
Related LinksTreatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. [Clin Microbiol Infect. 2005]The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. [Drugs. 2007]Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. [Pharmacotherapy. 2005][Current microbiological problems. Antibiotic resistance and therapeutic problems raised by Pseudomonas aeruginosa] [Presse Med. 1999]Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications. [Am J Pharmacogenomics. 2002]See all Related Articles...Display SummaryBriefAbstractAbstractPlusCitationMEDLINEXMLUI ListLinkOutASN.1Related ArticlesCited in BooksCancerChrom LinksDomain Links3D Domain LinksGEO DataSet LinksGene LinksGene (GeneRIF) LinksGenome LinksProject LinksGENSAT LinksGEO Profile LinksHomoloGene LinksCoreNucleotide LinksCoreNucleotide (RefSeq) LinksEST LinksEST (RefSeq) LinksGSS LinksGSS (RefSeq) LinksNucleotide LinksNucleotide (RefSeq) LinksOMIA LinksOMIM (calculated) LinksOMIM (cited) LinksBioAssay LinksCompound LinksCompound (MeSH Keyword)Compound (Publisher) LinksSubstance LinksSubstance (MeSH Keyword)Substance (Publisher) LinksPMC LinksCited in PMCPopSet LinksProbe LinksProtein LinksProtein (RefSeq) LinksProtein Cluster LinksCited ArticlesSNP LinksStructure LinksTaxonomy via GenBankUniGene LinksUniSTS Links Show 5102050100200500Sort ByPub DateFirst AuthorLast AuthorJournalSend toTextFilePrinterClipboardE-mailOrderWrite to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer
Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications.
Am J Pharmacogenomics. 2002; 2(4):235-43.